Dr. Hyung L. Kim
Claim this profileCedars Sinai Medical Center
Studies Prostate Cancer
Studies Skin Cancer
2 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Hyung L. Kim is currently running
Vytorin
for Prostate Cancer
To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate cancer patients who are in active surveillance and undergoing a planned surveillance biopsy in 3-6 months. Eligible patients will initiate iCL with Vytorin®(group 1, 2, and 3), an FDA-approved combination of ezetimibe and simvastatin used to lower atherogenic low density lipoprotein cholesterol (LDL-C) or Ezetimibe (group 4). Starting dose will be determined by current statin use and LDL-C levels. Dose modifications of VYTORIN will be employed with the goal of achieving LDL-C \<70 mg/dl. Dose adjustment is not allowed for ezetimibe.
Recruiting1 award Phase 22 criteria
Immunotherapy With or Without Surgery
for Kidney Cancer
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.
Recruiting2 awards Phase 316 criteria
More about Hyung L. Kim
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Hyung L. Kim has experience with
- Intensive Cholesterol-Lowering Therapy
- Avelumab
- Axitinib
- Cytoreductive Nephrectomy
- Ipilimumab
- Nivolumab
Breakdown of trials Hyung L. Kim has run
Prostate Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Hyung L. Kim specialize in?
Hyung L. Kim focuses on Prostate Cancer and Skin Cancer. In particular, much of their work with Prostate Cancer has involved treating patients, or patients who are undergoing treatment.
Is Hyung L. Kim currently recruiting for clinical trials?
Yes, Hyung L. Kim is currently recruiting for 2 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Hyung L. Kim has studied deeply?
Yes, Hyung L. Kim has studied treatments such as Intensive Cholesterol-Lowering Therapy, Avelumab, Axitinib.
What is the best way to schedule an appointment with Hyung L. Kim?
Apply for one of the trials that Hyung L. Kim is conducting.
What is the office address of Hyung L. Kim?
The office of Hyung L. Kim is located at: Cedars Sinai Medical Center, Los Angeles, California 90048 United States. This is the address for their practice at the Cedars Sinai Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.